88IV - PR Newswire Asia's news - Medical/Pharmaceuticals

< Previous page

| Title only | Print

Next page >

PharmaBlock's First Peptide GMP Pilot-scale Plant at PharmaBlock Zhejiang Site Now Operational Next-Generation Peptide CRDMO Solutions Enabled by a Green and Intelligent Platform for Empowering Global Innovative Drug Development ... 2026-06-04T Chemical Health Care/Hospital Medical/Pharmaceuticals
Innovative Drug Update \| Kexing Biopharm Enrolls First Subject in China-based Phase I Clinical Trial of Ophthalmic Innovative Drug GB10 SHENZHEN, China , June 4, 2026 /PRNewswire/ -- Recently, the first subject was enrolled and dosed in the Phase I clinical trial in China for GB10 Injection, an innovative ophthalmic drug independently ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Everest Medicines Enters Commercialization License Agreement with Mabworks for Bejescin® in the Asia-Pacific Market Everest Medicines has obtained exclusive rights for the clinical development and commercialization of Bejescin ® (MIL62, Obinutuzumab beta Injection) across the Asia-Pacific region, including Southeast ... 2026-06-04T Health Care/Hospital Medical/Pharmaceuticals
World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA SAN FRANCISCO and SUZHOU, China , June 4, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
Lupeng Pharmaceutical's Fourth-Generation BTK Inhibitor Rocbrutinib Approved in China for Relapsed or Refractory Mantle Cell Lymphoma GUANGZHOU, China , June 4, 2026 /PRNewswire/ -- Lupeng Pharmaceutical today announced that the National Medical Products Administration (NMPA) has granted accelerated approval to rocbrutinib (development ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
111, Inc. Announces First Quarter 2026 Unaudited Financial Results Continuing Transition toward a More Asset-Light and Operationally Efficient Business Model Net Revenue of Promotional Products (1) Increased by 70.2% and Gross Profit Rose by 75.0% Year-over-Year ... 2026-06-04T Health Care/Hospital Medical/Pharmaceuticals Retail
MEDIPOST Secures FDA Agreement on Single Pivotal Phase 3 Study with Confirmatory Evidence BLA Filing Strategy for CARTISTEM® in the U.S. SEOUL, South Korea , June 4, 2026 /PRNewswire/ -- MEDIPOST, a fully integrated commercial stage cell therapy biotechnology company, announced today that it has secured the FDA's agreement to conduct ... 2026-06-04T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
ERA Congress: Semaglutide linked to better quality of life in diabetes and kidney disease, FLOW trial shows GLASGOW, Scotland , June 4, 2026 /PRNewswire/ -- New findings from the landmark FLOW trial, presented at the 63 rd ERA Congress, show that once-weekly semaglutide significantly improved health-related ... 2026-06-04T Health Care/Hospital Medical/Pharmaceuticals
Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026 SHANGHAI and HONG KONG , June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ( "Antengene" , SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated ... 2026-06-03T Biotechnology Health Care/Hospital Medical/Pharmaceuticals
New Research Revealed Effective Surgical Management Techniques for Gynecomastia in Asian Men, Resulting in High Patient Satisfaction Between 2018 and 2023, Dr Ivan Puah treated over 550 cases, addressing unique challenges in Singapore's multi-ethnic population. His study included diverse case profiles. Results revealing no complications ... 2026-06-03T Health Care/Hospital Household/Consumer/Cosmetics Medical/Pharmaceuticals

< Previous page

Next page >

88iv | Home | Login

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer

Copyright (C) 2026

Suntek Computer Systems Limited.

All rights reserved